A novel single-chain antibody fragment for detection of mannose 6-phosphate-containing proteins: application in mucolipidosis type II patients and mice.

Newly synthesized soluble lysosomal hydrolases require mannose 6-phosphate (Man6P) residues on their oligosaccharides for their transport to lysosomes. The formation of Man6P residues is catalyzed by the GlcNAc-1-phosphotransferase, which is defective in the lysosomal storage disorders mucolipidosis type II (ML II) and ML III. Both hypersecretion and reduced intracellular level of lysosomal enzymes as well as direct sequencing of GlcNAc-1-phosphotransferase genes are important diagnostic markers for ML II and ML III. A high-affinity Man6P-specific single-chain antibody fragment was generated, allowing the rapid indirect demonstration of defective GlcNAc-1-phosphotransferase. In media and extracts of cultured fibroblasts of healthy controls but not of ML II and ML III patients, several Man6P-containing proteins could be detected by anti-Man6P Western blotting. Immunoprecipitation of Man6P-containing proteins from conditioned media or mouse brain extracts followed by arylsulfatase A and cathepsin D Western blotting confirmed the specificity of the antibody fragment for lysosomal proteins. Application of the antibody fragment in immunohistochemistry of human brain slices from nonaffected patients showed strong neuronal immunoreactivity, which was not observed in cortical sections of an ML II patient. Finally, in brain extracts of a novel GlcNAc-1-phosphotransferase knock-in mouse no Man6P-containing proteins were detectable. Thus, the single-chain antibody fragment against Man6P was demonstrated to allow the specific, rapid, and convenient detection of Man6P-containing proteins and facilitates the diagnosis of ML II and ML III.

[1]  A. Chabli,et al.  [Enzyme replacement therapy for lysosomal storage disorders]. , 2011, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[2]  T. Braulke,et al.  Glycosylation- and phosphorylation-dependent intracellular transport of lysosomal hydrolases , 2009, Biological chemistry.

[3]  D. Sleat,et al.  Proteomics of the lysosome. , 2009, Biochimica et biophysica acta.

[4]  J. Bonifacino,et al.  Sorting of lysosomal proteins. , 2009, Biochimica et biophysica acta.

[5]  A. Ballabio,et al.  Lysosomal disorders: from storage to cellular damage. , 2009, Biochimica et biophysica acta.

[6]  K. Ozono,et al.  Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype–phenotype correlation , 2009, Journal of Human Genetics.

[7]  Jung‐Ja P. Kim,et al.  Strategies for carbohydrate recognition by the mannose 6-phosphate receptors. , 2008, Glycobiology.

[8]  D. Sleat,et al.  Proteomics Analysis of Serum from Mutant Mice Reveals Lysosomal Proteins Selectively Transported by Each of the Two Mannose 6-Phosphate Receptors*S , 2008, Molecular & Cellular Proteomics.

[9]  H. Mandel,et al.  When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations in 24 patients. , 2006, Molecular genetics and metabolism.

[10]  W. Canfield,et al.  Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha / beta -subunits precursor gene. , 2006, American journal of human genetics.

[11]  B. Roe,et al.  The α- and β-subunits of the Human UDP-N-acetylglucosamine:Lysosomal Enzyme Phosphotransferase Are Encoded by a Single cDNA* , 2005, Journal of Biological Chemistry.

[12]  C. Ki,et al.  Identification of mutations in the GNPTA (MGC4170) gene coding for GlcNAc‐phosphotransferase α/β subunits in Korean patients with mucolipidosis type II or type IIIA , 2005, Human mutation.

[13]  C. Ki,et al.  Identification of mutations in the GNPTA (MGC4170) gene coding for GlcNAc-phosphotransferase alpha/beta subunits in Korean patients with mucolipidosis type II or type IIIA. , 2005, Human mutation.

[14]  B. Henrissat,et al.  Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. , 2005, Nature medicine.

[15]  T. Braulke,et al.  A novel mutation in UDP‐N‐acetylglucosamine‐1‐phosphotransferase gamma subunit (GNPTAG) in two siblings with mucolipidosis type III alters a used glycosylation site , 2004, Human mutation.

[16]  Jung‐Ja P. Kim,et al.  Structure of uPAR, plasminogen, and sugar‐binding sites of the 300 kDa mannose 6‐phosphate receptor , 2004, The EMBO journal.

[17]  A. Toutain,et al.  Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III , 2004, Journal of Medical Genetics.

[18]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[19]  A. Hasilik,et al.  A replacement of the active-site aspartic acid residue 293 in mouse cathepsin D affects its intracellular stability, processing and transport in HEK-293 cells. , 2003, The Biochemical journal.

[20]  J. Garin,et al.  Proteomic analysis of human lysosomes: Application to monocytic and breast cancer cells , 2002, Proteomics.

[21]  T. Braulke,et al.  MDCK cells secrete neutral proteases cleaving insulin-like growth factor-binding protein-2 to -6. , 2001, American journal of physiology. Endocrinology and metabolism.

[22]  B. Roe,et al.  Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC) , 2000, The Journal of clinical investigation.

[23]  C R MacKenzie,et al.  Quantitative analyses of binding affinity and specificity for glycolipid receptors by surface plasmon resonance. , 2000, Methods in enzymology.

[24]  T. Dierks,et al.  Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Lobel,et al.  Biophysical and Biological Properties of Naturally Occurring High Molecular Weight Insulin-like Growth Factor II Variants* , 1997, The Journal of Biological Chemistry.

[26]  C. MacKenzie,et al.  Bacterial expression and secretion of various single-chain Fv genes encoding proteins specific for a Salmonella serotype B O-antigen. , 1991, The Journal of biological chemistry.

[27]  K. von Figura,et al.  Insulin-like growth factors I and II stimulate endocytosis but do not affect sorting of lysosomal enzymes in human fibroblasts. , 1990, The Journal of biological chemistry.

[28]  S. Kornfeld,et al.  Ligand interactions of the cation-dependent mannose 6-phosphate receptor. Comparison with the cation-independent mannose 6-phosphate receptor. , 1989, The Journal of biological chemistry.

[29]  K. von Figura,et al.  Is movement of mannose 6-phosphate-specific receptor triggered by binding of lysosomal enzymes? , 1987, The Journal of cell biology.

[30]  A. Varki,et al.  Fibroblasts from patients with I-cell disease and pseudo-Hurler polydystrophy are deficient in uridine 5'-diphosphate-N-acetylglucosamine: glycoprotein N-acetylglucosaminylphosphotransferase activity. , 1981, The Journal of clinical investigation.

[31]  K. von Figura,et al.  Enzymatic phosphorylation of lysosomal enzymes in the presence of UDP-N-acetylglucosamine. Absence of the activity in I-cell fibroblasts. , 1981, Biochemical and biophysical research communications.

[32]  V. McKusick,et al.  Mucolipidosis III: clinical and laboratory findings. , 1975, Birth defects original article series.

[33]  R. Schmickel,et al.  Accumulation of 32S-mucopolysaccharides in cultured mucolipidosis cells. , 1975, Birth defects original article series.

[34]  H. Wiedemann,et al.  The genetic mucolipidoses. Diagnosis and differential diagnosis. , 1970, Humangenetik.